New data on clinical decisions in NSCLC patients with uncommon EGFR mutations.
Non-small cell lung cancer patients harboring uncommon epidermal growth factor receptor (EGFR) mutations together account for approximately 10% of all EGFR mutations. The most common of which being G719X, S768I, L861Q, and exon 20 insertions. The clinical significance, particularly their response to EGFR tyrosine kinase inhibitors (TKIs) is largely unclear. Previous data is limited to a small fraction of patients in prospective studies and retrospective series. Recently, a combined analysis of patients with uncommon EGFR mutations in the Lux-Lung 2, Lux-Lung 3, Lux-Lung 6 trials provide new perspectives of uncommon EGFR mutations. Areas covered: This review reports the existing evidence from major prospective and retrospective studies, along with new data that focus on the clinical significance of uncommon EGFR mutations. Expert commentary: The clinical data of uncommon EGFR mutations should be interpreted carefully as data from prospective and retrospective studies are not considered at the same level of evidence.